Full Professor(heuristic)

Prostate Cancer Treatment and Research · Pulmonary and Respiratory Medicine

h-index62
i10-index177
Publications630
Citations25,572

Grants

23 total · 6 active

NIH #5I01CX002189-04

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX002189-03

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX002189-02

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

23 total · 6 active

NIH #5I01CX002189-04

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX002189-03

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX002189-02

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #1I01CX002189-01A1

High-dose Testosterone in Men with Metastatic Castration-resistant Prostate Cancer and ATM or CDK12 deficiency

Expiring Soon
Amount
—
Period
2021-10-01 → 2026-09-30
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX001963-06

Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)

Active
Amount
—
Period
2020-01-01 → 2027-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX001963-05

Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)

Active
Amount
—
Period
2020-01-01 → 2027-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX001963-04

Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)

Amount
—
Period
2020-01-01 → 2024-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX001963-03

Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)

Amount
—
Period
2020-01-01 → 2024-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5I01CX001963-02

Carboplatin or Olaparib for BRcA deficient prostate cancer (COBRA)

Amount
—
Period
2020-01-01 → 2024-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #1I01CX001963-01

Multicenter phase II study of first-line carboplatin followed by docetaxel versus first-line docetaxel followed by carboplatin for treatment of castration resistant prostate cancer

Amount
—
Period
2020-01-01 → 2024-12-31
PIs
1

Awarded at VA PUGET SOUND HEALTHCARE SYSTEM

NIH #5M01RR000037-47

EGFR VACCINE TRIAL

Amount
$1K
Period
2007-04-01 → 2007-09-16
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5M01RR000037-46

A PHASE I STUDY OF AN EGFRVIII PEPTIDE-BASED VACCINE IN PATIENTS WITH CANCER

Amount
$11K
Period
2006-04-01 → 2007-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5R01CA082661-05

PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII

Amount
$207K
Period
1999-08-13 → 2006-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5M01RR000037-45

A PHASE I STUDY OF AN EGFRVIII PEPTIDE BASE VACCINE IN PATIENTS WITH CANCER

Amount
$24K
Period
2005-08-01 → 2006-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5R01CA082661-04

PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII

Amount
$201K
Period
1999-08-13 → 2005-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5R01CA082661-03

PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII

Amount
$196K
Period
1999-08-13 → 2005-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #2M01RR000037-44

A phase I study of an EGFRvIII peptide base vaccine in patients with cancer

Amount
$14K
Period
2004-08-06 → 2005-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #1R01CA082661-01

PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII

Amount
$190K
Period
1999-08-13 → 2003-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5K08CA060782-05

MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

Amount
$77K
Period
1993-09-07 → 1999-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5K08CA060782-04

MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

Amount
$77K
Period
1993-09-07 → 1999-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5K08CA060782-03

MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

Amount
$76K
Period
1993-09-07 → 1999-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #5K08CA060782-02

MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

Amount
$77K
Period
1993-09-07 → 1999-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

NIH #1K08CA060782-01

MODULATION OF RAS MEDIATED SIGNAL TRANSDUCTION

Amount
$77K
Period
1993-09-07 → 1999-04-30
PIs
1
Est. capacity / PI
~0 students

Awarded at UNIVERSITY OF WASHINGTON

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 58
Open author page on OpenAlex →